Editor in chief of Drug & Therapeutics Bulletin. Tweeting in a personal capacity.
Joined May 2009
- Tweets4.9K
- Following232
- Followers606
- Likes450
I would have thought somebody that ill would have avoided contact with everyone- tegardless of possible underlying cause- isnt that what COVID taught us? It shouldn’t require a doctor surely
James Cave retweeted
Medicines and global warming: a complex problem
Read the editorial by @JAHCave on why it's not just about swapping to dry powder inhalers and the importance of taking a holistic approach to tackling the issue.
bit.ly/4a5ZiIy
Now the session on Real World Data should be interesting. NICE is a founder member of the @GetRealinsti
#NICEConf23 some rather generic sessions so far in Manchester. Fascinating how X/Twitter has fallen by the wayside at these sorts of conferences. Gone has the live feeds. As said “ innovation has redundancy built in”
James Cave retweeted
Redaction at the heart of NICE appraisals
In the September editorial @JAHCave takes NICE to task over the amount of information that is redacted in its technical appraisals.
bit.ly/3ODzV9s
NICE produces technical appraisals of drugs to support clinicians and patients in their choice of the right treatments. Yet in 80% of their appraisals vital evidence and information is redacted. Our editorial in @DTB_BMJ this month dtb.bmj.com/content/early/20…
NICE’s TA on #mavacamten takes their redactions to a whole new level. Usually its just the less important stuff like the evidence of effectiveness or cost- but in this TA we arent even allowed to know what to use it for?
See nice.org.uk/guidance/gid-ta1…
#MHRA #NICE
James Cave retweeted
We are very pleased to learn that Australian Prescriber will resume publishing from its new home with Therapeutic Guidelines Limited. We look forward to reading the next issue.
bit.ly/41sKijH
James Cave retweeted
Top 10 Thursday
A countdown of the most accessed articles from 2022
6. What dose of paracetamol for people with low bodyweight? (DTB Select)
bit.ly/3zCm377
James Cave retweeted
What does the TIME study tell us about morning and evening dosing of antihypertensive medication? Read our commentary on the TIME study.
bit.ly/41xMXcd
Woken by the dawn chorus this morning #SpringIsComing but could have done without it at 05:15am
Relieved to see some action by ABPI after some blatant advertising : experts who praised new ‘skinny jab’ received payments from drug maker theguardian.com/business/202…
James Cave retweeted
Women in England will be able to get a year's worth of HRT for the cost of two single prescription charges (i.e. £18.70) from the 1 April
If you are as unhappy as i am at the new look medicines.org.uk and hate having to open multiple stems try just see the whole #spc I have found if you select the [print] option you can then scroll through the whole drug spc as before. #medicinescompendium
Fallacy- that a more convenient phone call frees up time. The call still takes an appointment- still requires all the governance of a F2F - perhaps more given the jeopardy of not being able to examine the patient. And ⬆️ convenience means ⬆️demand too
No. This is about inadequate service development and silo thinking. The Trust needs to be more patient focussed
A friend has been seen in her local MH assessment team and diagnosed with #ADHD. Because they’re not a specialist service they can’t prescribe stimulants, but can prescribe her pregabalin to manage her anxiety in the meantime. Policies round stimulants must change
Is that a Gender health gap? Or do 4 in 5 men feel the same. The way the nhs is currently I wonder if anyone feels listened to?
This Post is from an account that no longer exists. Learn more
